Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Kraus

Urogynecology and Reconstructive Pelvic Surgery San Antonio, TX Medical Doctor

NPI 1356458426 CMS profile 61017

8300 Floyd Curl Dr Fl 4, San Antonio, TX 78229

Open in the dashboard

General payments

$372,471

618 records reported · program years 2019–2025

Research payments

$6,810

Paid to them · 17 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Kraus of San Antonio, TX is reported in the CMS Open Payments database as having received $372,471 across 618 general payments and $6,810 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47,821 55
2024 General $39,221 80
2023 General $51,309 97
2022 General $87,240 135
2022 Research $526 2
2021 General $33,862 81
2021 Research $3,489 7
2020 General $39,675 65
2020 Research $2,496 7
2019 General $73,344 105
2019 Research $300 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Kraus
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Stephen Kraus were reported at $47,821. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Stephen Kraus Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $73,344 $799 $319–$2,013 $163
2020 $39,675 $384 $158–$1,360 $114
2021 $33,862 $641 $247–$2,515 $132
2022 $87,240 $843 $347–$2,794 $149
2023 $51,309 $819 $308–$2,302 $160
2024 $39,221 $882 $306–$2,459 $164
2025 $47,821 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $84,658 70 payments
  2. Sumitomo Pharma America, Inc. $60,174 64 payments
  3. Allergan Inc. $58,441 55 payments
  4. Urovant Sciences Inc $39,226 45 payments
  5. Astellas Pharma US Inc $38,945 40 payments
  6. Medtronic, Inc. $36,609 175 payments
  7. Astellas Pharma Global Development $21,175 6 payments
  8. GlaxoSmithKline, LLC. $10,947 5 payments
  9. Medtronic USA, Inc. $6,930 57 payments
  10. Laborie Medical Technologies Corp. $4,999 4 payments
  11. Other $10,368 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $265,933 95 payments
  2. Travel and Lodging $40,153 130 payments
  3. Consulting Fee $38,600 15 payments
  4. Food and Beverage $26,487 371 payments
  5. Honoraria $1,000 1 payment
  6. Education $260 5 payments
  7. Grant $39 1 payment
Products named General payments · program years 2019–2025
  1. GEMTESA $99,400 109 payments
  2. BOTOX Urology $95,331 74 payments
  3. MYRBETRIQ $59,860 41 payments
  4. INTERSTIM Sacral Nerve Stimulation $36,034 170 payments
  5. BOTOX Urology $26,396 30 payments
  6. BOTOX Urology $20,262 16 payments
  7. INTERSTIM Sacral Nerve Stimulation $6,910 56 payments
  8. Axonics $1,374 11 payments
  9. BLUDIGO $1,080 2 payments
  10. Bulkamid $883 10 payments
  11. Other $6,286 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Astellas Pharma Global Development $6,810 17 payments

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,156

Median for Urology: 1,053

Drug cost

$394,007

Median for Urology: $101,464

Branded share of claims

51.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 204 $200,763
Myrbetriq Mirabegron Brand 145 $149,348
Mirabegron Er Mirabegron Brand 27 $14,199
Trospium Chloride Generic 101 $10,439
Methenamine Hippurate Generic 89 $9,919
Tamsulosin Hcl Generic 165 $2,750
Oxybutynin Chloride Er Oxybutynin Chloride Brand 32 $2,603
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 70 $2,526
Finasteride Generic 86 $838
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 109 $386

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$127,847

Of which drugs: $27,118

Medicare patients

269

Average age 71

Services billed

6,227

122 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 38%
Depression 38%
Chronic kidney disease 32%
Ischemic heart disease 27%
Cancer 22%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 15 5,100 $25,428

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $14,213
$14,213 — 5,100
GEMTESA
  • Sumitomo Pharma America, Inc. $9,829
$9,829 204 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

635 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record